Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples
Abstract
Empagliflozin and sitagliptin are commonly co-administered to manage type 2 diabetes mellitus due to their complementary mechanisms of action on renal glucose reabsorption and insulin secretion, respectively. This synergistic effect enhances glycemic control with a minimal risk of hypoglycemia. In this study, a sensitive, simple, rapid, and selective spectrofluorimetric method was developed for the simultaneous determination of empagliflozin in the presence of sitagliptin in pharmaceutical formulations and spiked human plasma. Both drugs exhibit native fluorescence; however, their emission spectra significantly overlap, complicating their simultaneous analysis with conventional spectrofluorimetric techniques. To overcome this limitation, second-derivative synchronous spectrofluorimetry was applied. Measurements were performed within an optimized wavelength interval (Δλ = 60 nm), enabling selective determination of sitagliptin at 393 nm and empagliflozin at 310 nm without mutual interference. Experimental parameters affecting fluorescence intensity, including solvent type, pH, and Δλ, were carefully optimized to achieve maximum sensitivity and selectivity. The proposed method demonstrated excellent analytical performance, with limits of detection of 0.031 µg/mL and 0.011 µg/mL, and limits of quantification of 0.093 µg/mL and 0.033 µg/mL for sitagliptin and empagliflozin, respectively. Good linearity was observed over concentration ranges of 0.1-4 µg/mL for sitagliptin and…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.